SOX与XELOX方案对晚期胃癌患者血清肿瘤标志物及免疫功能的影响

Effects of SOX and XELOX Regimen on Serum Tumor Markers and Immune Function of Patients with Advanced Gastric Cancer

目的探讨SOX方案(奥沙利铂联合替吉奥)与XELOX方案(奥沙利铂联合卡培他滨)对晚期胃癌患者血清肿瘤标志物及免疫功能的影响。方法按照随机数字表法将2014年1月—2017年4月我院收治的124例晚期胃癌患者分为两组,各62例。对照组行XELOX方案化疗,观察组行SOX方案化疗,比较两组患者的临床疗效、血清肿瘤标志物[糖类抗原50(CA50)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原CA72-4(CA72-4)]、免疫功能(CD3^(+)、CD4^(+)、CD8^(+))、不良反应发生情况。结果观察组患者治疗有效率(54.84%)显著高于对照组(29.03%)(P<0.05);治疗后,两组患者血清CEA、CA199、CA50及CA72-4水平均显著低于治疗前,且观察组显著低于对照组(P<0.05);两组患者CD3^(+)、CD4^(+)及CD8^(+)水平均显著高于治疗前,且观察组显著高于对照组(P<0.05);两组患者白细胞减少、外周神经症状、血小板减少、腹泻、手足综合征、红细胞减少的发生率比较,差异均无统计学意义(P>0.05)。结论与XELOX方案相比,晚期胃癌患者行SOX方案化疗在提高临床疗效、降低血清肿瘤标志物水平和提高免疫功能等方面效果更佳,且不增加不良反应。

Objective To investigate the effects of SOX regimen(oxaliplatin combined with S-1) and XELOX regimen(oxaliplatin combined with capecitabine) on serum tumor markers and immune function of patients with advanced gastric cancer. Methods Totally 124 cases of patients with advanced gastric cancer in our hospital between January 2014 and April 2017 were divided into two groups by the random number table method, 62 cases in each group. The control group was given chemotherapy with XELOX regimen, while the observation group was given chemotherapy with SOX regimen. The clinical efficacy and the occurrence of adverse reactions were observed and compared between the two groups. The serum tumor markers [carbohydrate antigen 50(CA50), carcinoembryonic antigen(CEA), carbohydrate antigen 19-9(CA19-9), carbohydrate antigen 72-4(CA72-4) ], and immune function [CD3^(+), CD4^(+), CD8^(+)] were also compared between the two groups. Results The effective rate of patients in the observation group(54.84%) was higher than that of the control group(29.03%)(P<0.05). After treatment, the levels of CEA, CA19-9, CA50 and CA72-4 of patients were lower than those before treatment in both groups, and the levels of above mentioned indexes were lower in the observation group than in the control group(P<0.05). The levels of CD3^(+), CD4^(+) and CD8^(+) of patients in both groups were significantly higher than those before treatment, and they were significantly higher in the observation group than in the control group(P<0.05). No statistical differences were observed between the two groups in the incidence rate of leucopenia, peripheral nerve symptoms, low platelet count, diarrhea, hand-foot syndrome and erythropenia(P>0.05). Conclusion Compared with XELOX regimen, SOX regimen for patients with advanced gastric cancer had better results in increasing the clinical efficacy, decreasing serum levels of tumor markers, and improving immune function. The SOX regimen did not increase the incidence of adverse reactions of patients.